Showing results (1-10 of 43) with videos related to
Sort By:
Pageof 5
Current Cancer Drug Targets|December 20, 2003
Hypoxia inducible factor as a cancer drug targetSarah J Welsh, Garth PowisFuture Oncology (London, England)|April 3, 2015
Pazopanib for the treatment of renal cell carcinomaSarah J Welsh, Kate FifeTherapeutic Advances in Medical Oncology|March 11, 2015
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanomaSarah J Welsh, Pippa G CorrieActa Dermato-Venereologica|April 30, 2020
Biomarkers Predicting for Response and Relapse with Melanoma Systemic TherapySarah J Welsh, Pippa G CorrieSeminars in Oncology|August 8, 2006
The hypoxic inducible stress response as a target for cancer drug discoverySarah J Welsh, Mei Yee Koh, Garth PowisCancer Research|September 5, 2002
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesisSarah J Welsh, William T Bellamy, Margaret M Briehl, et al.European Journal of Cancer (Oxford, England : 1990)|May 28, 2016
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?Sarah J Welsh, Helen Rizos, Richard A Scolyer, et al.Seminars in Oncology|August 27, 2013
Adjuvant therapy in renal cell carcinoma-past, present, and futureTobias Janowitz, Sarah J Welsh, Kamarul Zaki, et al.Neoplasia (New York, N.Y.)|June 22, 2005
Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumorsIan F Robey, Anthony D Lien, Sarah J Welsh, et al.Molecular Cancer Therapeutics|March 27, 2003
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formationSarah J Welsh, Ryan R Williams, Anne Birmingham, et al.Pageof 5